Skip to content

Study on the treatment mode of stage IV diabetic retinopathy

Study on the treatment mode of stage IV diabetic retinopathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013555
Enrollment
Unknown
Registered
2017-11-27
Start date
2017-11-26
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy

Interventions

intravitreal injection of Lucentis:intravitreal injection of Lucentis
intravitreal injection of Lucentis combined with PRP laser treatment:intravitreal injection of Lucentis combined with PRP laser treatment
PRP laser treatment:PRP laser treatment

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Signd the informed consent form can be followed up according to the test plan; 2. Target eye with stage IV diabetic retinopathy: retinal neovascularization (NVE) or optic disc neovascularization (NVD), when NVD > 1/4-1/3DA or NVE is greater than 1/2DA, or with anterior retinal hemorrhage or vitreous hemorrhage, is called high-risk proliferative phase"; 3. Aged over 18 weeks, male and female; 4. Patient confirmed with diabetes whose blood sugar been controlled and stable; 5. glycosylated hemoglobin (HbAlc) less than 8.0%.

Exclusion criteria

Exclusion criteria: 1. Patients who have been treated with laser therapy; 2. Patients with severe cataracts, glaucoma or ocular active inflammation; 3. The target eye has traction retinal detachment, with or without vitreous hemorrhage; the target eye has been accepted within 3 months before the screening, or need intraocular surgery during the study period; 4. The affected eye is the only functional eye; 5. The target eye is associated with other retinal diseases, including central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), ocular ischemic syndrome, hypertensive retinopathy, etc.; 6. Target eye, non target eye or whole body system were treated with anti vascular endothelial growth factor (VEGF) TA and other drugs within 3 months before screening; 7. Preoperative routine examination results are abnormal, not suitable for eye surgery; 8. The researchers found that they were not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
EDTRS visual acuity test;Ultra wide angle fundus photography;Ultra wide angle fundus shadow;Color Optical Coherence Tomography;optometry;

Countries

China

Contacts

Public ContactFu Min

Zhujiang Hospital of Southern Medical University

min_fu1212@163.com+86 18665621066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026